Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21


Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: An open-label clinical study.

Kumar S, Chaudhury S.

Ind Psychiatry J. 2014 Jan;23(1):27-35. doi: 10.4103/0972-6748.144953.


Placebo response in antipsychotic clinical trials: a meta-analysis.

Rutherford BR, Pott E, Tandler JM, Wall MM, Roose SP, Lieberman JA.

JAMA Psychiatry. 2014 Dec 1;71(12):1409-21. doi: 10.1001/jamapsychiatry.2014.1319. Erratum in: JAMA Psychiatry. 2015 Jan;72(1):96.


Efficacy and tolerability of olanzapine in patients with schizophrenia in lithuania: A 13-week, multicenter, open-label, nonrandomized study.

Maciulis V, Bitter I, Milasiunas R, Dembinskas A, Radavicius L, Kaunas A, Dossenbach M, Walker D.

Curr Ther Res Clin Exp. 2004 Jan;65(1):57-69. doi: 10.1016/S0011-393X(04)90005-7.


Dose equivalents for second-generation antipsychotics: the minimum effective dose method.

Leucht S, Samara M, Heres S, Patel MX, Woods SW, Davis JM.

Schizophr Bull. 2014 Mar;40(2):314-26. doi: 10.1093/schbul/sbu001. Epub 2014 Feb 3.


The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial.

Chen L, Johnston JA, Kinon BJ, Stauffer V, Succop P, Marques TR, Ascher-Svanum H.

BMC Psychiatry. 2013 Nov 28;13:320. doi: 10.1186/1471-244X-13-320.


Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance.

Brunner E, Falk DM, Jones M, Dey DK, Shatapathy CC.

BMC Pharmacol Toxicol. 2013 Aug 1;14:38. doi: 10.1186/2050-6511-14-38. Review.


Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia.

Chen L, Ascher-Svanum H, Lawson A, Stauffer VL, Nyhuis A, Haynes V, Schuh K, Kinon BJ.

Neuropsychiatr Dis Treat. 2013;9:815-22. doi: 10.2147/NDT.S43574. Epub 2013 Jun 14.


Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database.

Turner EH, Knoepflmacher D, Shapley L.

PLoS Med. 2012;9(3):e1001189. doi: 10.1371/journal.pmed.1001189. Epub 2012 Mar 20.


Antipsychotic medication for early episode schizophrenia.

Bola J, Kao D, Soydan H.

Cochrane Database Syst Rev. 2011 Jun 15;(6):CD006374. doi: 10.1002/14651858.CD006374.pub2. Review.


How to obtain NNT from Cohen's d: comparison of two methods.

Furukawa TA, Leucht S.

PLoS One. 2011 Apr 27;6(4):e19070. doi: 10.1371/journal.pone.0019070.


Hyperprolactinemia associated with risperidone: a case report and review of literature.

Aboraya A, Fullen JE, Ponieman BL, Makela EH, Latocha M.

Psychiatry (Edgmont). 2004 Nov;1(3):29-31.


Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms.

de Greef R, Maloney A, Olsson-Gisleskog P, Schoemaker J, Panagides J.

AAPS J. 2011 Mar;13(1):121-30. doi: 10.1208/s12248-010-9247-4. Epub 2010 Dec 24.


Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study.

Geitona M, Kousoulakou H, Ollandezos M, Athanasakis K, Papanicolaou S, Kyriopoulos I.

Ann Gen Psychiatry. 2008 Aug 28;7:16. doi: 10.1186/1744-859X-7-16.


Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features.

Rabinowitz J, Levine SZ, Barkai O, Davidov O.

Schizophr Bull. 2009 Jul;35(4):775-88. doi: 10.1093/schbul/sbn005. Epub 2008 Feb 26.


Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research.

McMahon RP, Kelly DL, Boggs DL, Li L, Hu Q, Davis JM, Carpenter WT Jr.

Schizophr Bull. 2008 Mar;34(2):292-301. doi: 10.1093/schbul/sbm152. Epub 2008 Jan 8.


Olanzapine. Keep an eye on this neuroleptic.

[No authors listed]

Can Fam Physician. 2000 Feb;46:322-6, 330-6. English, French.


The use of atypical antipsychotics in the management of schizophrenia.

Campbell M, Young PI, Bateman DN, Smith JM, Thomas SH.

Br J Clin Pharmacol. 1999 Jan;47(1):13-22. Review.

Supplemental Content

Support Center